Boosting vitamin C levels may help curb leukemia risk

Boosting vitamin C levels may help curb leukemia risk

Boosting daily requirement of vitamin C may be helpful in curbing the development of leukemia, a deadly blood cancer, a study has found.Previous studies have shown that people with lower levels of ascorbate (vitamin C) are at an increased cancer risk but the reasons were not fully understood.Read also:Lack of Vitamin E in kids may affect learning skills

According to a study:

  • The new study showed that stem cells soak up unusually high levels of vitamin C.
  • In addition,which then regulates the cell function and suppresses the development of leukemia.
  • Stem cells use ascorbate to regulate the abundance of certain chemical modifications on DNA, which are part of the epigenome.
  • The epigenome is a set of mechanisms inside a cell that regulates which genes turn on and turn off.
  • So when stem cells don't receive enough vitamin C, the epigenome can become damaged in a way that increases stem cell function.
  • But also increases the risk of leukemia.
Read also:Food allergy can become fatal for your kid


  • This increased risk is partly tied to how ascorbate affects an enzyme known as Tet2.
  • Mutations that inactivate Tet2 are an early step in the formation of leukemia.
  • Ascorbate depletion can limit Tet2 function in tissues in a way that increases the risk of leukemia, the researchers explained.
  • Importantly, the findings have implications for older patients with a common precancerous condition known as clonal hematopoiesis.
  • It puts patients at a higher risk of developing leukemia and other diseases.
Read also:Increase in cigarette prices may reduce smoking in elderly

According to experts:

  • One of the most common mutations in patients with clonal hematopoiesis is a loss of one copy of Tet2.
  • Our results suggest patients with clonal hematopoiesis and a Tet2 mutation.
  • In addition, should be particularly careful to get 100 per cent of their daily Vitamin C requirement.
  • Because these patients only have one good copy of Tet2 left,
  • They need to maximise the residual Tet2 tumour-suppressor activity to protect themselves from cancer.

Share it
Share it
Share it